Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00006227?term=GOG-0187&rank=1

2. Intervention

   Paclitaxel

3. Additional Topic(s)

   Inhibin

4. Resource Description

   The purpose of this study is to estimate the probability of clinical response and toxicity of paclitaxel as second-line chemotherapy in measurable disease patients with malignant tumors of the ovarian stroma, and to evaluate the value of inhibin for predicting response.

5. Contact

   Berenberg, Jeffrey

6. PI

   Berenberg, Jeffrey

7. Topic

   ovarian cancer

8. Study Population

   Patients with histologically confirmed ovarian stromal tumor [granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell tumor (androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord stromal tumor, sex cord tumor with annular tubules], and meeting other disease and treatment related criteria.

9. Funded by

   Gynecologic Oncology Group

10. Phase

    Phase 2 clinical trial

11. Performed by

    Clinical Protocol & Data Management Shared Resource